【24h】

Impact of peritoneal dialysis dose guidelines on clinical outcomes.

机译:腹膜透析剂量指南对临床结局的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The objective was to review the rationale for the Kidney Disease Outcomes Quality Initiative (K/DOQI) recommendations for adequacy of peritoneal dialysis and to evaluate the impact of these recommendations on clinical practice and patient survival. The K/DOQI recommendations were based on large observational studies; the target weekly Kt/V value of 2.0 assumed equivalence of peritoneal and renal clearances. This assumption is no longer considered correct. The impact on clinical practice was evaluated by an examination of temporal trends before and after publication of the guidelines in 1997. In the United States and The Netherlands, there had been a trend toward increased delivered total Kt/V prior to 1997, and there was no acceleration in this trend after 1997. Two randomized clinical trials have implemented these guidelines with increased peritoneal Kt/V (or creatinine clearance) used to achieve the K/DOQI target in the intervention group. This was not associated with improved survival, compared to alower Kt/V, in either of the randomized clinical trials. Among the explanations for the failure to improve outcome are potential adverse effects of increasing the dialysis dose. These include increased intraperitoneal pressure associated with increased exchange volume, failure to increase clearance of middle molecules, and increased exposure to glucose. Strategies that increase peritoneal clearance without exposure to these potential adverse effects include more-frequent exchanges rather than increased exchange volume, and decreased exposure to glucose and glucose degradation products. Pending such studies, current K/DOQI guidelines should be updated in a timely manner.
机译:目的是审查肾病结果质量倡议(K / DOQI)建议进行腹膜透析充分性的理由,并评估这些建议对临床实践和患者生存的影响。 K / DOQI建议基于大型观察研究;每周目标Kt / V值2.0假定腹膜和肾脏清除率相等。该假设不再被认为是正确的。通过检查该指南在1997年发布前后的时间趋势来评估其对临床实践的影响。在美国和荷兰,1997年之前有一种交付总Kt / V增加的趋势,并且在1997年之后,这种趋势没有加速。两项随机临床试验已采用增加腹膜Kt / V(或肌酐清除率)的指南来实现干预组中的K / DOQI目标。在任何一项随机临床试验中,与较低的Kt / V相比,这均与生存率的提高无关。未能改善治疗效果的解释包括增加透析剂量的潜在不利影响。这些包括与交换量增加相关的腹膜内压力增加,无法增加中间分子的清除率以及增加的葡萄糖暴露。在不暴露于这些潜在不良影响的情况下增加腹膜清除率的策略包括更频繁的交换而不是增加交换量,以及减少对葡萄糖和葡萄糖降解产物的暴露。在进行此类研究之前,应及时更新当前的K / DOQI指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号